ProfileGDS5678 / 1435444_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 71% 70% 76% 73% 70% 73% 75% 73% 72% 74% 73% 73% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1803868
GSM967853U87-EV human glioblastoma xenograft - Control 24.4400771
GSM967854U87-EV human glioblastoma xenograft - Control 34.4085170
GSM967855U87-EV human glioblastoma xenograft - Control 45.2336176
GSM967856U87-EV human glioblastoma xenograft - Control 54.7372173
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3539270
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6836973
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9315875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7295173
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.624872
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8144774
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7919973
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6973
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6746873